Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2704]

Platform-predicted treatments improve outcomes for platinum-resistant ovarian cancer

Platform-predicted treatments improve outcomes for platinum-resistant ovarian cancer

FDA approves durvalumab for muscle invasive bladder cancer

FDA approves durvalumab for muscle invasive bladder cancer

FDA expands lutetium Lu 177 vipivotide tetraxetan’s metastatic castration-resistant prostate cancer indication

FDA expands lutetium Lu 177 vipivotide tetraxetan’s metastatic castration-resistant prostate cancer indication

Researchers identify mutations that can lead to resistance to some chemotherapies

Researchers identify mutations that can lead to resistance to some chemotherapies

FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours

FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours

Research discovers a way to slow or block recurrence of glioblastoma

Research discovers a way to slow or block recurrence of glioblastoma

Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy

Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy

Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy demonstrates promising antitumor activity with acceptable safety as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, single-arm trial

Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy demonstrates promising antitumor...

New drug therapy combination shows promise for advanced melanoma patients

New drug therapy combination shows promise for advanced melanoma patients

Breakthrough combination therapy tackles drug resistance in lung cancer with common KRAS mutation

Breakthrough combination therapy tackles drug resistance in lung cancer with common KRAS mutation

More from ecancer